Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease
Hannes Hagström, Patrik Nasr, Mattias Ekstedt et al. · Scandinavian Journal of Gastroenterology · 2016
BACKGROUND AND AIM: Moderate alcohol consumption has been associated with a lower risk of disease severity in non-alcoholic fatty liver disease (NAFLD). It is unclear if this reflects current or lifetime drinking, or can be attributed to confounders such as diet and exercise. We evaluated the impact of lifetime alcohol consumption on fibrosis severity in NAFLD. METHODS: We prospectively enrolled 120 subjects with biopsy-proven NAFLD and through detailed questionnaires examined lifetime alcohol consumption, diet and physical activity. Main outcome measures were odds ratios (OR) for fibrosis stage, calculated through ordinal regression after adjustment for body mass index, diabetes mellitus type 2, smoking and age at biopsy. A biomarker for recent alcohol consumption, phosphatidyl ethanol (PEth) was sampled. RESULTS: An increase in median weekly alcohol consumption to a maximum of 13 drinks per week was associated with lower fibrosis stage (adjusted OR for each incremental unit, 0.86; 95% CI, 0.76-0.97; p = .017). The lowest risk for fibrosis was found with the lowes`t odds seen in the top quartile of alcohol consumption (aOR 0.23; 95% CI 0.08-0.66; p = .006). Adding soft drink and coffee consumptions, and physical activity to the model did not change the estimates. Subjects with PEth ≥0.3 μmol/L had higher ORs for a higher fibrosis stage (aOR 2.77; 95% CI 1.01-7.59; p = .047). CONCLUSION: Lifetime alcohol consumption with up to 13 units per week is associated with lower fibrosis stage in NAFLD. Elevated PEth is associated with higher stages of fibrosis.
Cited by 95 works. doi:10.1080/00365521.2016.1239759
Authors
- Hannes Hagström
- Patrik Nasr
- Mattias Ekstedt
- Stergios Kechagias
- Kristina Önnerhag
- Emma Nilsson
- Fredrik Rorsman
- Reza Sheikhi
- Hanns–Ulrich Marschall
- Rolf W. Hultcrantz
- Per I Stal
References
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
- Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption‐II
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
- Alcohol Consumption and Mortality among Middle-Aged and Elderly U.S. Adults
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
- The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
- the Incidence and Risk Factors of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis
- Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis
- The global NAFLD epidemic